Skip to main content
. 2022 Nov 16;54(1):3234–3249. doi: 10.1080/07853890.2022.2136403

Table 1.

Demographic and clinical data of convalescent coronavirus disease 2019 (COVID-19) patients and controls in included datasets.

Study Subjects (n) Males n (%) Age (years) BMI (kg/m2) Diabetes n (%) Hypertension n (%) Hypercholesterolaemia n (%) Smokinga n (%) SBP (mmHg) DBP (mmHg) CAD n (%)
Ambrosino et al. [4] 133 COVID-19 108 (81.2) 61.6 21 (15.8) 68 (51.1) 12 (9.0) 12 (9.0) 19 (14.3)
133 Controls 107 (80.5) 60.4 23 (17.3) 74 (55.6) 14 (10.5) 12 (9.0) 24 (18.0)
Çiftel et al. [31] 38 COVID-19 20 (52.6) 8.9 19.6 0 0 0 0 99.6 61.5 0
38 Controls 20 (52.6) 8.9 20.1 0 0 0 0 108.9 68.2 0
Ergül et al. [32] 63 COVID-19
29 Controls 0 0 0 0
Gao et al. [33] (a) 86 COVID-19 32 (37.2) 55.7 24.0 14 (16.3) 32 (37.2) 16 (18.6) 131.0 76.3 13 (15.1)
28 Controls 10 (35.7) 52.7 23.0 0 0 0 125.0 74.0 0
Gao et al. [33] (b) 86 COVID-19 32 (37.2) 55.7 24.0 14 (16.3) 32 (37.2) 16 (18.6) 131.0 76.3 13 (15.1)
30 –Controls 11 (36.7) 58.7 24.0 2 (6.7) 10 (33.3) 9 (30.0) 126.0 72.7 3 (10.0)
Jud et al. [17] (a) 14 COVID-19 7 (50.0) 68.7 29.4 0 6 (42.9) 6 (42.9) 6 (42.9) 0
14 controls 7 (50.0) 30.7 23.8 0 0 0 8 (57.1) 0
Jud et al. [17] (b) 14 COVID-19 7 (50.0) 68.7 29.4 0 6 (42.9) 6 (42.9) 6 (42.9) 0
14 Controls 7 (50.0) 66.9 27.6 4 (28.6) 13 (92.9) 12 (85.7) 11 (78.6) 8 (57.1)
Lambadiari et al. [34] (a) 70 COVID-19 44 (62.9) 54.5 0 0 0 16 (22.9)c 129.7 78.2 0
70 Controls 44 (62.9) 54.8 0 0 0 21 (30.0)c 126.6 80.7 0
Lambadiari et al. [34] (b) 70 COVID-19 44 (62.9) 54.5 0 0 0 16 (22.9)c 129.7 78.2 0
70 Controls 44 (62.9) 54.5 0 70 (100) 0 18 (25.7)c 145.3 89.9 0
Mansiroglu et al. [37] 80 COVID-19 32 (40.0) 32.1 25.6 2 (2.5) 2 (2.5) 1 (1.3) 19 (23.8) 105.0 70.0 0
81 Controls 41 (44.4) 30.5 20.0 2 (2.5) 2 (2.5) 1 (1.2) 23 (28.4) 110.0 70.0 0
Nandadeva et al. [35] (a) 8 COVID-19 1 (12.5) 24.0 26.0 0 0 0 0 111.0 70.0 0
12 Controls 6 (50.0) 23.0 23.0 0 0 0 0 112.0 66.0 0
Nandadeva et al. [35] (b) 8 COVID-19 5 (62.5) 22.0 22.0 0 0 0 0 110.0 68.0 0
12 controls 6 (50.0) 23.0 23.0 0 0 0 0 112.0 66.0 0
Oikonomou et al. [15] (a) 55 COVID-19 32 (58.2) 57.8 12 (21.8) 21 (38.2) 14 (25.5)b 129.0 80.0 3 (5.5)
55 Controls 29 (52.7) 62.6 17 (30.9) 28 (50.9) 15 (27.3)b 135.0 80.0 3 (5.5)
Oikonomou et al. [15] (b) 55 COVID-19 32 (58.2) 57.8 12 (21.8) 21 (38.2) 14 (25.5)b 132.0 81.0 3 (5.5)
55 Controls 29 (52.7) 62.6 17 (30.9) 28 (50.9) 15 (27.3)b 135.0 80.0 3 (5.5)
Ratchford et al. [16] 11 COVID-19 4 (36.4) 20.1 23.5 0 0 0 0 121.3 71.8 0
20 Controls 5 (25.0) 23.0 22.5 0 0 0 0 111.8 77.7 0
Riou et al. [36] 27 COVID-19 17 (63.0) 57.3 29.7 7 (25.9) 13 (48.1) 6 (22.2) 134.0 84.7
9 Controls 5 (55.6) 58.3
Skow et al. [18] 23 COVID-19 9 (39.1) 23.0 25.3 0 0 0 0 109.0 67.0 0
13 Controls 6 (46.1) 26.0 25.7 0 0 0 0 113.0 69.0 0

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; CAD: coronary artery disease.

Continuous data are reported as mean values, unless otherwise indicated. The minus sign indicates that the information has not been specifically provided and/or cannot be inferred from the text of the article.

aAny smoking history.

bDyslipidaemia.

cCurrent smokers.